PR Newswire
EMERYVILLE, Calif. , Sept. 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021 .
The on demand presentation will be available, beginning Monday, September 13, 2021 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations .
About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn .
Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264
Derek Cole , President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
SOURCE Dynavax Technologies